US pharma giant pulls out of AHMM’s King’s Cross life sciences scheme

Merck 2025 2

Decision blamed on declining competitiveness of UK market

Mace is again up against ISG for the next phase of work on an office and life sciences centre opposite King’s Cross station in London.

This content is available to registered users | Already registered?Login here

You are not currently logged in.

To continue reading this story, sign up for free guest access

Existing Subscriber? LOGIN

REGISTER for free access on selected stories and sign up for email alerts. You get:

  • Up to the minute architecture news from around the UK
  • Breaking, daily and weekly e-newsletters

 

Subscribe to Building Design and you will benefit from:

Gated access promo

  • Unlimited news
  • Reviews of the latest buildings from all corners of the world
  • Technical studies
  • Full access to all our online archives
  • PLUS you will receive a digital copy of WA100 worth over £45

Subscribe now for unlimited access.